Paper24045166
Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level.
Kmiecik J and 7 others. J Neuroimmunol, 2013. Cited by 334 papers, by iCite.
Cite this record
ConductScience Library. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. Papers, record 24045166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24045166
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level.
- PubMed
Topics23
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Brain Neoplasms | Major topic |
| CD28 Antigens | Major topic |
| CD3 Complex | Major topic |
| Glioblastoma | Major topic |
| Lymphocytes, Tumor-Infiltrating | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Antigens, CD | |
| CTLA-4 Antigen | |
| Child | |
| Female | |
| Follow-Up Studies | |
| Forkhead Transcription Factors | |
| Humans | |
| Immunosuppressive Agents | |
| Kaplan-Meier Estimate | |
| Macrophages | |
| Male | |
| Microglia | |
| Middle Aged | |
| Young Adult |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT05106725 | Wearable Devices and Biomarkers Project (Healthiomics) | Background | ClinicalTrials.gov | |
| NCT05831631 | Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors | Background | ClinicalTrials.gov |
Cited by274
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 334 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42619051 | The Imbalance Between Tumor Immunosurveillance and Tumor Immune Escape in Glioblastoma. | Immunol Cell Biol | 2026 | https://conductscience.org/library/papers/42619051 | PubMed |
| 42375809 | Crosstalk in the brain tumor microenvironment: mechanisms, therapeutic strategies, and clinical advances. | Mil Med Res | 2026 | https://conductscience.org/library/papers/42375809 | PubMed |
| 42062602 | Histopathological, immunohistochemical, and molecular characterization of Coenurus cerebralis infection in sheep with evaluation of cerebrospinal cytokine responses. | Parasitol Res | 2026 | https://conductscience.org/library/papers/42062602 | PubMed |
| 41929521 | Natural killer cell dysfunction in glioma: from immune evasion to immunotherapy. | Front Immunol | 2026 | https://conductscience.org/library/papers/41929521 | PubMed |
| 41789657 | Cellular and inflammatory characteristics of patient‑derived glioblastoma organoids during in vitro cultivation. | Oncol Rep | 2026 | https://conductscience.org/library/papers/41789657 | PubMed |
| 41652635 | Precision oncology in a dish: patient-derived glioma organoids to guide novel therapeutic strategies. | Biomark Res | 2026 | https://conductscience.org/library/papers/41652635 | PubMed |
| 41507535 | Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity. | Nat Cancer | 2026 | https://conductscience.org/library/papers/41507535 | PubMed |
| 41268299 | Brain microenvironment orchestrates highly aggressive tumor variants: current trends and therapeutic approaches. | Front Aging Neurosci | 2025 | https://conductscience.org/library/papers/41268299 | PubMed |
| 41105161 | T cell immunity in glioma and potential implications for immunotherapy: A systematic review. | Neuro Oncol | 2026 | https://conductscience.org/library/papers/41105161 | PubMed |
| 41053233 | The promise of immunotherapy for central nervous system tumours. | Nat Rev Immunol | 2026 | https://conductscience.org/library/papers/41053233 | PubMed |
| 41001043 | Development of a novel prognostic model for mantle cell lymphoma based on quantitative detection of CD3 by quantitative dot blot. | Front Oncol | 2025 | https://conductscience.org/library/papers/41001043 | PubMed |
| 40933033 | The glioma microenvironment and its impact on antitumor immunity. | Neurooncol Adv | 2025 | https://conductscience.org/library/papers/40933033 | PubMed |
| 40867165 | Unraveling Glioblastoma Heterogeneity: Advancing Immunological Insights and Therapeutic Innovations. | Brain Sci | 2025 | https://conductscience.org/library/papers/40867165 | PubMed |
| 40596223 | Single-dose radiotherapy is more effective than fractionation when combined with anti-PD-1 immunotherapy in glioblastoma. | Sci Rep | 2025 | https://conductscience.org/library/papers/40596223 | PubMed |
| 40591036 | Carboxypeptidase Q(CPQ) promotes glioma progression by inducing M2 macrophage polarization and immunosuppression. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40591036 | PubMed |
| 40524972 | Evaluating the Diagnostic and Prognostic Value of Peripheral Immune Markers in Glioma Patients: A Prospective Multi-Institutional Cohort Study of 1282 Patients. | J Inflamm Res | 2025 | https://conductscience.org/library/papers/40524972 | PubMed |
| 40361496 | Reduced HLA-I Transcript Levels and Increased Abundance of a CD56dim NK Cell Signature Are Associated with Improved Survival in Lower-Grade Gliomas. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40361496 | PubMed |
| 40265144 | Blood-Based Prognostic Prediction Model for Glioblastoma: Construction and Validation. | Cancer Manag Res | 2025 | https://conductscience.org/library/papers/40265144 | PubMed |
| 40236954 | Rat Sarcoma (RAS)-Protein-Targeting Synthetic Cell-Penetrating Peptide as an Anticancer Biomaterial. | Biomater Res | 2025 | https://conductscience.org/library/papers/40236954 | PubMed |
| 40215269 | Single-cell dissection of the genotype-immunophenotype relationship in glioblastoma. | Brain | 2025 | https://conductscience.org/library/papers/40215269 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD28 | 940 | PubTator's text mining | https://conductscience.org/library/genes/940 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| CTLA4 | 1493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| ENTPD1 | 953 | PubTator's text mining | https://conductscience.org/library/genes/953 | NCBI Gene |
| FOXP3 | 50943 | PubTator's text mining | https://conductscience.org/library/genes/50943 | NCBI Gene |
| IL10 | 3586 | PubTator's text mining | https://conductscience.org/library/genes/3586 | NCBI Gene |
| MGMT | 4255 | PubTator's text mining | https://conductscience.org/library/genes/4255 | NCBI Gene |
| NT5E | 4907 | PubTator's text mining | https://conductscience.org/library/genes/4907 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24045166
GET https://conductscience.org/api/papers/v1/24045166/cited_by?page=2